Off-label use of Sorafenib in patients with advanced thyroid carcinoma: Retrospective analysis of five cases

Research output: Contribution to journalArticle

Abstract

We present results obtained in five patients with advanced thyroid cancer, derived from the follicular epithelium, treated with Sorafenib used off-label. The median age at the time Sorafenib was started was 61 years. Only one patient tolerated the standard dose of 400 mg twice daily. The most severe adverse events were:.

Original languageEnglish
Pages (from-to)1084-1087
Number of pages4
JournalJournal of cancer research and therapeutics
Volume12
Issue number2
DOIs
Publication statusPublished - 2016

Keywords

  • I-131 refractory
  • kinase inhibitor
  • Sorafenib
  • thyroid carcinoma
  • PHASE-II TRIAL
  • DOUBLE-BLIND
  • CANCER
  • PAPILLARY
  • EFFICACY

Cite this